USFDA determines inspection classification of VAI for the contract manufacturing facility at Spokane, Washington

Jubilant Pharmova Limited ('Company') today announced that, Jubilant HollisterStier LLC ('JHS') has received a communication from the USFDA, through which the regulatory agency intimated that pursuant to its audit of JHS's contract manufacturing facility located at Spokane, Washington (USA) from May 28,2024 to June 6, 2024, it has determined the inspection classification of the facility as "Voluntary Action Indicated" (VAI).

Jubilant HollisterStier LLC is a subsidiary of Jubilant Pharma Holding Inc., which is a subsidiary of Jubilant Pharma Limited, Singapore, a wholly owned subsidiary of the company.

Shares of Jubilant Pharmova Limited was last trading in BSE at Rs. 1017.30 as compared to the previous close of Rs. 1030.40. The total number of shares traded during the day was 40834 in over 2287 trades.

The stock hit an intraday high of Rs. 1044.60 and intraday low of 1010.80. The net turnover during the day was Rs. 41845102.00.

Source : Equity Bulls

Keywords

JubilantPharmova INE700A01033 USFDA JubilantHollisterStierLLC Audit Spokane Washington ManufacturingFacility VAI